Pre-chemotherapy treatment delays return of aggressive lymphoma
In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.
In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.
Treatment with autologous engineered T cells is effective bridge to potentially curative therapy
Melanoma tumors create conditions that attract immunoglobulin G4 (IgG4), the B-cell antibody class least effective in activating immune response.
Interim results confirmed the “unprecedented” single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.
The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.
A newly discovered molecular marker can distinguish aggressive chronic lymphocytic leukemia from a less aggressive form.
When induction therapy fails in acute lymphoblastic leukemia, some youths have better outcomes with more chemotherapy than with stem cell transplant.
The drug ibrutinib can provide significant anticancer responses with modest side effects in persons with diffuse large B-cell lymphomas (DLBCLs).
The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia rose from 83.7% for 1990-1994 to 90.4% for 2000-2005.
Survival improved significantly for persons younger than 60 years with diffuse large B-cell lymphoma when they underwent intensified chemotherapy compared with the standard regimen.